Dean Y Li Merck & Co., Inc. (MRK) insider trading activity

Dean Y Li is Executive VP & President, MRL of Merck & Co., Inc.. Currently has a direct ownership of 46,242 shares of MRK, which is worth approximately $5.25 Million. The most recent transaction as insider was on Feb 09, 2024, when has been sold 14,702 shares (Common Stock) at a price of $125.5 per share, resulting in proceeds of $1,845,101. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 46.2K

0% 3M change

125.89% 12M change

Total Value Held $5.25 Million

Dean Y Li Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 09 2024	SELL Open market or private sale	$1,845,101 $125.5 p/Share	14,702 Reduced 24.12%	46,242 Common Stock
Feb 09 2024	BUY Exercise of conversion of derivative security	$912,553 $62.07 p/Share	14,702 Added 19.44%	60,944 Common Stock
Jan 22 2024	BUY Grant, award, or other acquisition	$3,076,516 $119.43 p/Share	25,760 Added 35.78%	46,242 Common Stock
May 01 2023	SELL Payment of exercise price or tax liability	$60,506 $115.47 p/Share	524 Reduced 2.5%	20,471 Common Stock
May 01 2023	BUY Exercise of conversion of derivative security	$122,629 $115.47 p/Share	1,062 Added 4.81%	20,995 Common Stock
Jan 23 2023	BUY Grant, award, or other acquisition	$359,857 $109.88 p/Share	3,275 Added 14.11%	19,933 Common Stock
May 03 2022	SELL Payment of exercise price or tax liability	$33,395 $87.65 p/Share	381 Reduced 2.26%	16,457 Common Stock
May 03 2022	BUY Exercise of conversion of derivative security	$67,753 $87.65 p/Share	773 Added 4.39%	16,838 Common Stock
May 01 2022	SELL Payment of exercise price or tax liability	$46,385 $88.69 p/Share	523 Reduced 3.15%	16,065 Common Stock
May 01 2022	BUY Exercise of conversion of derivative security	$94,100 $88.69 p/Share	1,061 Added 6.01%	16,588 Common Stock
Feb 24 2022	BUY Grant, award, or other acquisition	$222,221 $73.51 p/Share	3,023 Added 16.35%	15,462 Common Stock
May 04 2021	SELL Payment of exercise price or tax liability	$18,083 $75.98 p/Share	238 Reduced 1.9%	12,309 Common Stock
May 04 2021	BUY Exercise of conversion of derivative security	$52,730 $75.98 p/Share	694 Added 5.24%	12,547 Common Stock
May 03 2021	SELL Payment of exercise price or tax liability	$19,146 $74.5 p/Share	257 Reduced 2.12%	11,853 Common Stock
May 03 2021	BUY Exercise of conversion of derivative security	$55,875 $74.5 p/Share	750 Added 5.83%	12,110 Common Stock
May 01 2021	SELL Payment of exercise price or tax liability	$26,373 $74.5 p/Share	354 Reduced 3.02%	11,360 Common Stock
May 01 2021	BUY Exercise of conversion of derivative security	$76,735 $74.5 p/Share	1,030 Added 8.08%	11,714 Common Stock
Feb 26 2021	BUY Grant, award, or other acquisition	$253,081 $72.62 p/Share	3,485 Added 24.65%	10,655 Common Stock

Also insider at

RXRX

RECURSION PHARMACEUTICALS, INC. Healthcare

Director

DYL

Dean Y Li

Executive VP & President, MRL

Kenilworth, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MRK shares.

Notify only if

Value

Insider Trading

Get notified when an Merck & Co., Inc. insider buys or sells MRK shares.

Notify only if

Operation

Value

Type

News

Receive news related to Merck & Co., Inc.

Track Activities on MRK

Account